{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:15:35Z","timestamp":1791274535345,"version":"4.1.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1016\/j.neuropharm.2008.06.033","type":"journal-article","created":{"date-parts":[[2008,6,28]],"date-time":"2008-06-28T08:42:01Z","timestamp":1214642521000},"page":"517-524","source":"Crossref","is-referenced-by-count":48,"title":["Peripheral administration of group III mGlu receptor agonist ACPT-I exerts potential antipsychotic effects in rodents"],"prefix":"10.1016","volume":"55","author":[{"given":"A.","family":"Pa\u0142ucha-Poniewiera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"K\u0142odzi\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Stachowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Tokarski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Hess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Schann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Frauli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Neuville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Pilc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2008.06.033_bib1","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0893-133X(00)00250-5","article-title":"Effects of single and repeated phencyclidine administration of the expression of metabotropic glutamate receptor subtype mRNAs in rat brain","volume":"25","author":"Abe","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2008.06.033_bib2","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/S0165-0173(99)00046-6","article-title":"Serotonin model of schizophrenia: emerging role of glutamate mechanisms","volume":"31","author":"Aghajanian","year":"2000","journal-title":"Brain Res. Rev."},{"key":"10.1016\/j.neuropharm.2008.06.033_bib3","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/S0022-3565(24)35047-5","article-title":"Characterization of MK-801-induced behavior as a putative rat model of psychosis","volume":"290","author":"Andine","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2008.06.033_bib4","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1124\/mol.107.035170","article-title":"A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis","volume":"72","author":"Benneyworth","year":"2007","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2008.06.033_bib5","first-page":"212","article-title":"Action de la caf\u00e9ine sur la motilit\u00e9 spontan\u00e9e de la souris","volume":"158","author":"Boissier","year":"1965","journal-title":"Arch. Int. Pharmacodyn. Ther."},{"key":"10.1016\/j.neuropharm.2008.06.033_bib6","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1046\/j.1471-4159.2000.0750889.x","article-title":"Regulation of neurotransmitter release by metabotropic glutamate receptors","volume":"75","author":"Cartmell","year":"2000","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2008.06.033_bib7","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0022-3565(24)35084-0","article-title":"The metabotropic glutamate 2\/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats","volume":"291","author":"Cartmell","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2008.06.033_bib8","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/sj.npp.1300678","article-title":"Dopamine is not required for the\u00a0hyperlocomotor response to NMDA receptor antagonists","volume":"30","author":"Chartoff","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2008.06.033_bib9","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0006-8993(77)90645-X","article-title":"Stereotyped behavior patterns and hyperactivity induced by amphetamine and apomorphine after discrete 6-hydroxydopamine lesions of extrapyramidal and mesolimbic nuclei","volume":"123","author":"Costall","year":"1977","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2008.06.033_bib10","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2174\/1568007024606212","article-title":"Ionotropic glutamate receptors as therapeutic targets in schizophrenia","volume":"1","author":"Coyle","year":"2002","journal-title":"Curr. Drug Targets CNS Neurol. Disord."},{"key":"10.1016\/j.neuropharm.2008.06.033_bib11","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0014-2999(90)94066-7","article-title":"Withdrawal from chronic treatment with (+\/\u2212)-DOI causes super-sensitivity to 5-HT2 receptor-induced head-twitch behaviour in mice","volume":"186","author":"Darmani","year":"1990","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2008.06.033_bib12","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1124\/jpet.105.091074","article-title":"A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2\/3 receptor agonist in mouse models predictive of antipsychotic activity","volume":"315","author":"Galici","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2008.06.033_bib13","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1124\/jpet.106.102046","article-title":"Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice","volume":"318","author":"Galici","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2008.06.033_bib14","doi-asserted-by":"crossref","first-page":"6879","DOI":"10.1523\/JNEUROSCI.15-10-06879.1995","article-title":"Multiple presynaptic metabotropic glutamate receptors modulate excitatory and inhibitory synaptic transmission in hiocampal area CA1","volume":"15","author":"Gereau","year":"1995","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2008.06.033_bib15","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0893-133X(00)00136-6","article-title":"Behavioral evidence for interactions between a hallucinogenic drug and Group II metabotropic glutamate receptors","volume":"23","author":"Gewirtz","year":"2000","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2008.06.033_bib16","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.pnpbp.2003.09.003","article-title":"Animal behavior models of the mechanisms underlying antipsychotic atypicality","volume":"27","author":"Geyer","year":"2003","journal-title":"Prog. Neuro-psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2008.06.033_bib17","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1016\/0024-3205(84)90436-3","article-title":"Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents","volume":"35","author":"Glennon","year":"1984","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2008.06.033_bib18","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nature06612","article-title":"Identification of a serotonin\/glutamate receptor complex implicated in psychosis","volume":"452","author":"Gonzalez-Maeso","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2008.06.033_bib19","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.pain.2007.08.020","article-title":"Group III metabotropic glutamate receptors inhibit hyperalgesia in animal models of inflammation and neuropathic pain","volume":"137","author":"Goudet","year":"2008","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2008.06.033_bib20","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/brain\/122.4.593","article-title":"The neuropathology of schizophrenia. A critical review of the data and their interpretation","volume":"122","author":"Harrison","year":"1999","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2008.06.033_bib21","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/0091-3057(94)90554-1","article-title":"Dopamine receptor antagonists block amphetamine- and phencyclidine-induced motor stimulation in rats","volume":"48","author":"Jackson","year":"1994","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2008.06.033_bib22","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0091-3057(02)00845-6","article-title":"Group II mGlu receptor agonists inhibit behavioural and electrophysiological effects of DOI in mice","volume":"73","author":"K\u0142odzi\u0144ska","year":"2002","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2008.06.033_bib23","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.neuroscience.2006.12.006","article-title":"The influence of group III metabotropic glutamate receptor stimulation by (1S,3R,4S)-1-aminocyclo-pentane-1,3,4-tricarboxylic acid on the parkinsonian-like akinesia and striatal proenkephalin and prodynorphin mRNA expression in rats","volume":"145","author":"Konieczny","year":"2007","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2008.06.033_bib24","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00213-003-1582-z","article-title":"NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development","volume":"169","author":"Krystal","year":"2003","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.neuropharm.2008.06.033_bib25","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1152\/jn.1995.73.3.1076","article-title":"Metabotropic glutamate receptor-mediated presynaptic depression at corticostriatal synapses involves mGluR2 or 3","volume":"73","author":"Lovinger","year":"1995","journal-title":"J.\u00a0Neurophysiol."},{"key":"10.1016\/j.neuropharm.2008.06.033_bib26","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1111\/j.1460-9568.1995.tb01051.x","article-title":"Metabotropic glutamate receptors inhibiting excitatory synapses in the CA1 area of rat hippocampus","volume":"7","author":"Manzoni","year":"1995","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2008.06.033_bib27","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/0028-3908(95)00060-J","article-title":"Pharmacology of metabotropic glutamate receptors at the mossy fiber synapses of the guinea pig hippocampus","volume":"34","author":"Manzoni","year":"1995","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2008.06.033_bib28","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S0022-3565(24)35262-0","article-title":"Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex","volume":"292","author":"Marek","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2008.06.033_bib29","doi-asserted-by":"crossref","first-page":"R9","DOI":"10.1016\/0014-2999(95)00333-G","article-title":"Blockade of phencyclidine-induced hyperlocomotion by clozapine and MDL 100,907 in rats reflects antagonism of 5-HT2A receptors","volume":"280","author":"Maurel-Remy","year":"1995","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2008.06.033_bib30","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1152\/jn.1985.54.4.782","article-title":"Comparative electrophysiology of pyramidal and sparsely spiny stellate neurons of the neocortex","volume":"54","author":"McCormick","year":"1985","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.neuropharm.2008.06.033_bib31","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00213-004-1792-z","article-title":"Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia","volume":"174","author":"Moghaddam","year":"2004","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2008.06.033_bib32","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1126\/science.281.5381.1349","article-title":"Reversal of phencyclidine effects by a group\u00a0II metabotropic glutamate receptor agonist in rats","volume":"281","author":"Moghaddam","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2008.06.033_bib33","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1523\/JNEUROSCI.17-08-02921.1997","article-title":"Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex","volume":"17","author":"Moghaddam","year":"1997","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2008.06.033_bib34","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1021\/jm980616n","article-title":"Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2- aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and\u00a0systemically active agonists for group II metabotropic glutamate receptors","volume":"42","author":"Monn","year":"1999","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2008.06.033_bib35","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1128\/AAC.36.10.2156","article-title":"Central nervous system targeting of 2\u2032,3\u2032-dideoxyinosine via adenosine deaminase-activated 6-halo-dideoxypurine prodrugs","volume":"36","author":"Morgan","year":"1992","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.neuropharm.2008.06.033_bib36","first-page":"295","article-title":"Potential antipsychotic and extrapyramidal effects of (R,S)-3,4-dicarboxyphenylglycine [(R,S)-3,4-DCPG], a mixed AMPA antagonist\/mGluR8 agonist","volume":"56","author":"Ossowska","year":"2004","journal-title":"Pol. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2008.06.033_bib37","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.pharmthera.2007.04.007","article-title":"Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs","volume":"115","author":"Palucha","year":"2007","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2008.06.033_bib38","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.neuropharm.2003.09.006","article-title":"Group III mGlu receptor agonists produce anxiolytic- and antidepressant-like effects after central administration in rats","volume":"46","author":"Pa\u0142ucha","year":"2004","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2008.06.033_bib39","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/nm1632","article-title":"Activation of mGlu2\/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial","volume":"13","author":"Patil","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2008.06.033_bib40","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.brainres.2007.03.028","article-title":"Evaluation of the mGlu8 receptor as a putative therapeutic target in schizophrenia","volume":"1152","author":"Robbins","year":"2007","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2008.06.033_bib41","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00213-007-0758-3","article-title":"In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2\/3 receptor agonist LY404039 in animal models of psychiatric disorders","volume":"193","author":"Rorick-Kehn","year":"2007","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.neuropharm.2008.06.033_bib42","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0022-3565(24)29296-X","article-title":"Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system","volume":"299","author":"Schoepp","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2008.06.033_bib43","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1152\/jn.1997.77.2.527","article-title":"Presynaptic modulation by metabotropic glutamate receptors of excitatory and inhibitory synaptic inputs to hypothalamic magnocellular neurons","author":"Schrader","year":"1997","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.neuropharm.2008.06.033_bib44","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/S0028-3908(99)00092-1","article-title":"Pharmacological agents acting at subtypes of metabotropic glutamate receptors","volume":"38","author":"Schoepp","year":"1999","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2008.06.033_bib45","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s10519-006-9120-5","article-title":"Animal models relevant to schizophrenia and autism: validity and limitations","volume":"37","author":"Tordjman","year":"2007","journal-title":"Behav. Genet."},{"key":"10.1016\/j.neuropharm.2008.06.033_bib46","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/0014-2999(95)00560-9","article-title":"Metabotropic glutamate group II receptors are responsible for the depression of synaptic transmission induced by ACPD in the dentate gyrus","volume":"294","author":"Ugolini","year":"1995","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2008.06.033_bib47","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0301-0082(91)90019-W","article-title":"The regulation of quantal size","volume":"36","author":"Van der Kloot","year":"1991","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2008.06.033_bib48","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/(SICI)1098-1063(1998)8:6<566::AID-HIPO2>3.0.CO;2-W","article-title":"Neurochemistry and pharmacology of the major hippocampal transmitter systems: Synaptic and nonsynaptic interactions","volume":"8","author":"Vizi","year":"1998","journal-title":"Hippocampus"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839080800230X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839080800230X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T21:52:56Z","timestamp":1738273976000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002839080800230X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["S002839080800230X"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2008.06.033","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2008,9]]}}}